Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$163.22 USD
-0.94 (-0.57%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $163.16 -0.06 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.22 USD
-0.94 (-0.57%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $163.16 -0.06 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Zacks News
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
by Zacks Equity Research
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
by Sundeep Ganoria
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
by Kinjel Shah
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
by Zacks Equity Research
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHQ
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
by Kinjel Shah
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.